Figure 1.
Flow diagram of patients included in ESVEA analysis within the Find-AF trial. 281 were included in the Find-AF trial, 237 without AF at presentation received 7-day Holter-ECG-monitoring. 229 Holter-ECGs were analysed. ESVEA analysis was possible in 208 cases, 23 of which showed at least one episode of PAF.
Table 1.
Clinical Characteristics.
Figure 2.
Distribution of patients with longest episode of atrial fibrillation in 7-day Holter-monitoring in the respective category. Divisions were chosen based on trials indicating an increased thromboembolic risk above the respective cut-off: 6 min. as shown to increase stroke risk within the ASSERT-trial [24], 6 hours (5.5 hours) as presented by the TRENDS-study investigators [28] and 24 hours as identified within the Italian AT-500 registry [29]. 30 seconds as defined as minimal duration of atrial fibrillation by current AF guidelines [30].
Figure 3.
PAF detection on 7-day holter in relation to PACs on 24-hour-Holter.
Percentage of patients with paroxysmal atrial fibrillation on 7-day Holter-monitoring across quartiles of PACs/h detected within a 24-hour episode free from PAF.
Figure 4.
ROC-curves – ESVEA as a predictor of PAF.
ROC-curves for PAC/h (blue) and SV-run24 h (green) to detect paroxysmal atrial fibrillation A) in baseline 7-day Holter-monitoring only or B) total PAF after baseline 7-day Holter-monitoring and clinical follow-up (up to 1 year).